Hillstream Biopharma Stock EBITDA
Hillstream Biopharma fundamentals help investors to digest information that contributes to Hillstream Biopharma's financial success or failures. It also enables traders to predict the movement of Hillstream Stock. The fundamental analysis module provides a way to measure Hillstream Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Hillstream Biopharma stock.
Hillstream |
Hillstream Biopharma Company EBITDA Analysis
Hillstream Biopharma's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Hillstream Biopharma EBITDA | (6.88 M) |
Most of Hillstream Biopharma's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Hillstream Biopharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
CompetitionAccording to the company disclosure, Hillstream Biopharma reported earnings before interest,tax, depreciation and amortization of (6.88 Million). This is 100.78% lower than that of the Biotechnology sector and 106.87% lower than that of the Health Care industry. The ebitda for all United States stocks is 100.18% higher than that of the company.
Hillstream EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Hillstream Biopharma's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Hillstream Biopharma could also be used in its relative valuation, which is a method of valuing Hillstream Biopharma by comparing valuation metrics of similar companies.Hillstream Biopharma is currently under evaluation in ebitda category among its peers.
Hillstream Fundamentals
Return On Equity | -1.47 | |||
Return On Asset | -0.78 | |||
Current Valuation | 496.66 K | |||
Shares Outstanding | 17.53 M | |||
Shares Owned By Insiders | 38.90 % | |||
Shares Owned By Institutions | 0.80 % | |||
Number Of Shares Shorted | 52.74 K | |||
Price To Book | 0.88 X | |||
EBITDA | (6.88 M) | |||
Net Income | (8.47 M) | |||
Cash And Equivalents | 9.48 M | |||
Cash Per Share | 0.82 X | |||
Total Debt | 772.9 K | |||
Current Ratio | 13.13 X | |||
Book Value Per Share | 0.18 X | |||
Cash Flow From Operations | (6.56 M) | |||
Short Ratio | 0.20 X | |||
Earnings Per Share | (0.76) X | |||
Target Price | 4.0 | |||
Market Capitalization | 4.23 M | |||
Total Asset | 6.69 M | |||
Retained Earnings | (15.38 M) | |||
Working Capital | 5.54 M | |||
Z Score | -2.34 | |||
Net Asset | 6.69 M |
Thematic Opportunities
Explore Investment Opportunities
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Other Consideration for investing in Hillstream Stock
If you are still planning to invest in Hillstream Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Hillstream Biopharma's history and understand the potential risks before investing.
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Commodity Directory Find actively traded commodities issued by global exchanges |